A correlation and red, amber, green (RAG) analysis of Boditech i-CHROMA™ Prostate Specific Antigen (PSA) Point of Care Test (POCT) Method and Roche PSA laboratory methods

Authors

  • John Bolodeoku Medical Health Laboratories, New Malden, United Kingdom
  • Terry Gbaa Medical Health Laboratories, New Malden, United Kingdom
  • Chidi Anyaeche Medical Health Laboratories, New Malden, United Kingdom
  • Michael Bass Medical Health Laboratories, New Malden, United Kingdom
  • Jonathan Makanjuola Department of Urology, King Edward VII Memorial Hospital, Hamilton, Bermuda
  • Tae Kyum Kim Boditech Med Inc, y Dongnae-myeon, Chuncheon-si, Gangwon-do, Korea
  • Frank Chinegwundoh Department of Urology, Barts Health NHS Trust, Royal London Hospital, Whitechapel, London, UK; and School of Health Sciences, University of London, London, UK

DOI:

https://doi.org/10.51496/jogm.v2.113

Keywords:

PSA, POCT, iCHROMA, Roche, Prostate Cancer

Abstract

Background: This study evaluated and compared the performance of the Boditech i-CHROMA™ point-of-care testing (POCT) method for the quantification of prostate-specific antigen (PSA) against traditional laboratory PSA method (Roche Methods – Roche Cobas c303/501/502/503, Roche Cobas e402/ e801 and Roche Cobas e411) using external quality control material from RIQAS.

Materials and method: External quality control distributions from RIQAS were analysed using the Boditech i-CHROMA™ PSA method; these were then compared with the results of the Roche Methods – Roche Cobas c303/501/502/503, Roche Cobas e402/ e801 and Roche Cobas e411 provided by participants in the scheme. The mean results of the Roche methods were compared using linear regression and Red Amber Green (RAG) analysis, a scoring system where red is indicative of a raised PSA (>6.0 ng/mL), amber is indicative of a slightly raised PSA (5.0 – 6.0 ng/mL). Green indicates a normal PSA (<5.0 ng/mL).

Results: The data showed that between the Boditech i-CHROMA™ PSA results and the Roche Cobas c303/501/502/503, there was an excellent correlation (r2 = 0.9843). The RAG analysis showed the Boditech i-CHROMA™ PSA method identified 26 reds, two ambers, and six greens compared with 27 reds, two ambers, and six greens determined by the Roche Cobas c303/501/502/503 method. The data showed an excellent correlation between the Boditech i-CHROMA™ PSA results and the Roche Cobas e402/ e801 PSA methods (r2 = 0.9842). The RAG analysis showed the Boditech i-CHROMA™ PSA method identified 30 reds, three ambers, and eight greens compared with 31 reds, two ambers, and eight greens identified by the Roche Cobas e402/ e801 PSA methods. The data showed an excellent correlation between the Boditech i-CHROMA™ PSA results and the Roche Cobas e411 PSA methods (r2 = 0.9851). The RAG analysis showed the Boditech i-CHROMA™ PSA method identified 30 reds, three ambers, and eight greens compared with 31 reds, two ambers, and eight greens identified Roche Cobas e411 PSA methods.

Conclusion: The data showed that the Boditech i-CHROMA™ PSA method is comparable to the Roche Cobas c303/501/502/503, Roche Cobas e402/ e801 and Roche Cobas e411 PSA methods. This could effectively reduce the turnaround time to make prompt decisions on diagnosing, treating, and monitoring of patients with prostate-related disorders.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394–424. doi: 10.3322/caac.21492 DOI: https://doi.org/10.3322/caac.21492

Hinata N, Fujisawa M. Racial differences in prostate cancer characteristics and cancer-specific mortality: an overview. World J Mens Health 2022; 40(2): 217. doi: 10.5534/wjmh.210070 DOI: https://doi.org/10.5534/wjmh.210070

Burford DC, Kirby M, Austoker J. Prostate cancer risk management programme: information for primary care; PSA testing in asymptomatic men. Evidence document. NHS Cancer Screening Programmes. 2010.

Park H-I, Lee S, Kim Y, Shin D-Y, Lee C, Han S, et al. Analytical performance of a new one-step quantitative prostate-specific antigen assay, the FRENDTM PSA Plus. Clin Chem Lab Med 2014; 52(5): 715–23. doi: 10.1515/cclm-2013-0545 DOI: https://doi.org/10.1515/cclm-2013-0545

Karim O, Rao A, Emberton M, Cochrane D, Partridge M, Edwards P, et al. Point-of-care PSA testing: an evaluation of PSAwatch. Prostate Cancer Prostatic Dis 2007; 10(3): 270–3. doi: 10.1038/sj.pcan.4500962 DOI: https://doi.org/10.1038/sj.pcan.4500962

Ashida S, Yamasaki I, Kawada C, Fukuhara H, Fukata S, Tamura K. et al. Evaluation of a rapid one-step PSA test for primary prostate cancer screening. BMC Urol 2021; 135(2021). doi: 10.1186/s12894-021-00903-7 DOI: https://doi.org/10.1186/s12894-021-00903-7

Srinivasan B, Nanus DM, Erickson D, Mehta S. Highly portable quantitative screening test for prostate-specific antigen at point of care. Curr Res Biotechnol 2021; 3: 288–99. doi: 10.1016/j.crbiot.2021.11.003 DOI: https://doi.org/10.1016/j.crbiot.2021.11.003

Rausch S, Hennenlotter J, Wiesenreiter J, Hohneder A, Heinkele J, Schwentner C. et al. Assessment of a new point-of-care system for detection of prostate specific antigen. BMC Urol. 2016;16:4. doi: 10.1186/s12894-016-0119-9 DOI: https://doi.org/10.1186/s12894-016-0119-9

Ajala AO, Adedeji TA, Busuyi JS. A comparative study of prostate specific antigen (PSA) Point-of-Care-Testing (POCT) techniques. Ann Health Res 2023; 9(1): 43–50. doi: 10.30442/ahr.0901-05-189 DOI: https://doi.org/10.30442/ahr.0901-05-189

Bolodeoku J, Bains S, Chand V, Bacon RJ, Weir P, Miles V. et al. An evaluation of the point-of-care test i-CHROMA prostate-specific antigen method for screening in the community. Point of Care 2017; 16(2): 93–6. doi: 10.1097/POC.0000000000000131 DOI: https://doi.org/10.1097/POC.0000000000000131

Beltran L, Leach E, Bolodeoku J, de Fonseka S, Chinegwundoh F. An evaluation of the Novel i-CHROMATM Point-of-Care Testing (POCT) method for the analysis of prostate-specific antigen (PSA) in serum. Biomed J Sci Tech Res 2018; 9(4). doi: 10.26717/BJSTR.2018.09.001822 DOI: https://doi.org/10.26717/BJSTR.2018.09.001822

Bolodeoku J, Coker O, Bains S, Chinegwundoh F. The performance of the point of care test (poct) i-chroma™ psa method using internal and external quality assessment schemes: united kingdom external quality assessment service (ukneqas) and randox international quality assessment service. Curr Trends Med Diagn Meth: CTMDM-104 2018; doi: 10.29011/CTMDM-104.100004

Downloads

Published

12-11-2023

How to Cite

Bolodeoku, J., Gbaa, T. ., Anyaeche, C. ., Bass, M. ., Makanjuola, J., Kim, T. K., & Chinegwundoh, F. (2023). A correlation and red, amber, green (RAG) analysis of Boditech i-CHROMA™ Prostate Specific Antigen (PSA) Point of Care Test (POCT) Method and Roche PSA laboratory methods. Journal of Global Medicine, 3(1), e113. https://doi.org/10.51496/jogm.v2.113

Issue

Vol. 3 No. 1 (2023)

Section

Research Articles

Categories

License

Copyright (c) 2023 John Bolodeoku, Terry Gbaa, Chidi Anyaeche, Michael Bass, Jonathan Makanjuola, Tae Kyum Kim, Frank Chinegwundoh

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC